"Epithelial surfaces in the human body are not only a physical barrier - they are crucial in maintaining healthy relationships with our microbiome and orchestrating defences against pathogens."
Professor Gudmundur Gudmundsson
CSO & Founder
OUR THERAPEUTIC FOCUS
Gastrointestinal mucositis is a key driver of mortality during cancer and transplant therapy
Epithelial tissues serve as a critical barrier, lining both internal and external surfaces of the body, while actively contributing to the immune system through dynamic immunological functions. Many cancer therapies and stem cell transplant conditioning treatments compromise the integrity of the gut mucosa, leading to severe complications such as gastrointestinal mucositis (CIGM) which manifests as inflammation, serious infections , and elevated treatment-related mortality rates.
Akthelia Pharmaceuticals is targeting this prevalent pathology with its innovative host-directed therapy, AKT-011, designed to prevent and treat mucosal barrier injury. With a primary focus on CIGM in oncology, the therapy also holds promise for broader applications across skin, airway, gut, oral mucosa, and urogenital system disorders, as well as systemic infections and inflammatory conditions, aiming to transform patient outcomes with a new standard of care.
UNIQUE HOST-DIRECTED APPROACH
Therapeutic science leveraging the power of millions of years of cooperative evolution
Decades of research by our founding scientists, have led us to a powerful therapeutic approach that mimics and enhances the effects of natural metabolites released by microbiota to maintain the integrity and health of their epithelial niche.
Our candidate therapeutic molecules are designed to amplify these effects, enhancing the immune status of the epithelial surface, restoring its barrier function and rejuvenating its relationships with the surrounding biology.
OUR LATEST NEWS
PARTNERS
Our
Collaborators
Great science needs great partners and we're proud to be collaborating with so many best-in-class organisations and research institutions to drive our research and development efforts forwards.
UNIVERSITY OF ICELAND
KAROLINSKA INSTITUTE
THERAINDX LIFESCIENCES
EVOTEC
ENAMINE BIENTA
UNIVERSITY OF NORTH TEXAS
RECIPHARM
MEWBURN ELLIS